Rabies composition comprising PIKA adjuvant
The present disclosure provides a rabies composition comprising IPRV and PIKA adjuvant, and the pharmaceutical use thereof. The present disclosure also discloses a method for prophylaxis or therapeutic treatment of rabies virus infection, the method comprises a step of administering the rabies vaccine composition to a host. The rabies composition is more stable and safe, and is able to induce earlier and higher titers of neutralizing antibody.
1. A rabies vaccine composition, comprising:
a) inactivated purified rabies virus (IPRV),
b) PIKA adjuvant, and
c) human serum albumin (HSA);
wherein
the amount of IPRV is from 0.5 IU to 3.0 IU per unit dose,
the amount of PIKA adjuvant is from 250 μg to 3000 μg per unit dose, and
the amount of HSA is from 0.1% to 0.9% by concentration.
2. The rabies vaccine composition according to claim 1 , wherein the amount of said IPRV is selected from the group consisting of 0.5 IU, 1.0 IU, 1.5 IU, 2.0 IU, 2.5 IU, and 3.0 IU per unit dose, and the range between any two of the following amounts: 0.5 IU, 1.0 IU, 1.5 IU, 2.0 IU, 2.5 IU, and 3.0 IU per unit dose.
3. The rabies vaccine composition according to claim 2 , wherein the amount of said IPRV is from 0.5 IU to 3.0 IU per unit dose or from 1.0 IU to 2.5 IU per unit dose.
4. The rabies vaccine composition according to claim 1 , wherein the amount of said PIKA adjuvant is selected from the group consisting of 250 μg, 500 μg, 1000 μg, 1500 μg, 2000 μg, and 3000 μg per unit dose, and the range between any two of the following amounts: 250 μg, 500 μg, 1000 μg, 1500 μg, 2000 μg, and 3000 μg per unit dose.
5. The rabies vaccine composition according to claim 4 , wherein the amount of said PIKA adjuvant is between from 500 μg to 3000 μg per unit dose, or from 1000 μg to 3000 μg, or from 1500 μg to 2500 μg, or about 2000 μg per unit dose.
6. The rabies vaccine composition according to claim 1 , wherein the amount of said HSA is selected from the group consisting of 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, and 0.6% by concentration, and the range between any two of the following amounts: 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, and 0.6% by concentration.
7. The rabies vaccine composition according to claim 1 , wherein the ratio of IPRV to PIKA adjuvant is selected from the group consisting of: 1 IU/100 μg, 1 IU/125 μg, 1 IU/200 μg, 1 IU/250 μg, 1 IU/300 μg, 1 IU/350 μg, 1 IU/400 μg, 1 IU/450 μg, 1 IU/500 μg, 1 IU/550 μg, 1 IU/600 μg, 1 IU/700 μg, 1 IU/800 μg, 1 IU/1000 μg, 1 IU/1500 μg, and 1 IU/2000 μg, and the ratio between any two of the following ratios: 1 IU/100 μg, 1 IU/125 μg, 1 IU/200 μg, 1 IU/250 μg, 1 IU/300 μg, 1 IU/350 μg, 1 IU/400 μg, 1 IU/450 μg, 1 IU/500 μg, 1 IU/550 μg, 1 IU/600 μg, 1 IU/700 μg, 1 IU/800 μg, 1 IU/1000 μg, 1 IU/1500 μg, and 1 IU/2000 μg.
8. The rabies vaccine composition according to claim 1 , wherein the amount of IPRV is 2.0 IU per unit dose, and the amount of PIKA adjuvant is 1000 μg per unit dose.
9. The rabies vaccine composition according to claim 1 , wherein the amount of IPRV is 2.0 IU per unit dose, the amount of PIKA adjuvant is 2000 μg per unit dose, and the amount of HSA is 0.3% by concentration.
10. The rabies vaccine composition according to claim 1 , wherein the amount of IPRV is 1.5 IU per unit dose, the amount of PIKA adjuvant is 2000 μg per unit dose, and the amount of HSA is 0.3% by concentration.
11. The rabies vaccine composition according to claim 1 , wherein the amount of IPRV is 2.0 IU per unit dose, the amount of PIKA adjuvant is 1000 μg per unit dose, and the amount of HSA is 0.5% by concentration.
12. The rabies vaccine composition according to claim 1 , wherein said composition does not comprise gelatin.
13. The rabies vaccine composition according to claim 1 , wherein said composition further comprises maltose, wherein the amount of said maltose is between 1.0% and 6.0% by concentration.
14. The rabies vaccine composition according to claim 1 , wherein said IPRV is selected from the group consisting of CTN strain, PM strain, aG strain, and PV strain.
15. The rabies vaccine composition according to claim 1 , wherein said IPRV is prepared in Vero cell or primary hamster kidney cell.
16. The rabies vaccine composition according to claim 1 , wherein said composition is in a liquid form or a lyophilized form.
17. A pharmaceutical kit, comprising or consisting of:
a) the rabies vaccine composition of claim 1 ,
b) a vial,
c) an instruction for use, and
d) optionally water for injection;
wherein said instruction for use suggests the following administration regimen:
1) 2-2-1 regimen for post exposure treatment: 2 unit dose administered on days 0, 2 unit dose administered on days 3, and 1 unit dose administered on days 7 post exposure; and/or
2) 2-1 regimen for prophylaxis: 2 unit dose administered on days 0 and 1 unit dose administered on days 7.
18. A method for treatment or prevention of rabies caused by rabies virus infection or inducing an immune response to rabies virus infection, wherein the method comprises a step of administering the rabies vaccine composition of claim 1 to a host, wherein said host has been exposed to rabies virus.
19. The method according to claim 18 , wherein the rabies vaccine composition of claim 1 is administered to the host for 5 times within 7 days post exposure of rabies virus.
20. The method according to claim 19 , wherein the rabies vaccine composition of claim 1 is administered to the host based on the following regimen:
a first administration on 0 day post exposure,
a second administration on 0 day post exposure,
a third administration on 2 or 3 day post exposure,
a fourth administration on 2 or 3 day post exposure, and
a fifth administration on 6 or 7 day post exposure, respectively.
21. The method according to claim 18 , wherein the rabies vaccine composition of claim 1 is administered to a host based on the following regimen:
a 1st and a 2nd administration on 0 day post exposure,
a 3rd and a 4th administration on 2 or 3 day post exposure, and
a 5th and/or a 6th administration on 7 day post exposure, respectively.
22. A method for prophylaxis of rabies caused by rabies virus infection or inducing an immune response to a rabies virus, the method comprises a step of administering the rabies vaccine composition of claim 1 to a host, wherein said host is not exposed to rabies virus.
23. The method according to claim 22 , wherein the rabies vaccine composition of claim 1 is administered to the host for 3 times within 7 days.
24. The method according to claim 23 , wherein the rabies vaccine composition of claim 1 is administered to the host based on the following regimen:
a first administration on day 0,
a second administration on day 0, and
a third administration on day 7, respectively.
25. The method according to claim 18 , wherein said administration is by intramuscular injection, intradermal delivery, transdermal delivery, subcutaneous injection, parenteral injection, intraperitoneal injection, intravenous injection, inhalation, rectal delivery, nasal delivery, oral delivery, or topical delivery.
26. A method of medical treatment, wherein the method involves administering the rabies vaccine composition according to claim 1 five or six times within seven days.
27. The method according to claim 26 , wherein the method involves administering the rabies vaccine composition based on the following regimen:
a 1st and a 2nd administration on 0 day post exposure,
a 3rd and a 4th administration on 2 or 3 day post exposure, and
a 5th and/or a 6th administration on 7 day post exposure, respectively.
28. A method of prevention of rabies, wherein the method involves administering the rabies vaccine composition according to claim 1 three times within seven days.
29. The method according to claim 28 , wherein the method of prevention involves administering the rabies vaccine composition based on the following regimen:
a first administration on day 0,
a second administration on day 0, and
a third administration on day 7, respectively.